How Multiomics and Artificial Intelligence Are Transforming Localized NSCLC: A Deep Dive Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

How Multiomics and Artificial Intelligence Are Transforming Localized NSCLC: A Deep Dive
@pateloncology.bsky.social @ucsdhealth.bsky.social #AI #LCSM #ILCC2025
www.onclive.com/view/how-mul...

Dr Reckamp on the Future Implications of the PRAGMATICA-LUNG Trial in Lung Cancer Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

WATCH: Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer. #ILCC2025 #gotoPER #lcsm
www.onclive.com/view/dr-reck...

Dr Das on Updates to the Standard First-Line Treatment Paradigm for ES-SCLC Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer.

WATCH: Millie Das, MD, discusses first-line standards of care for patients with extensive-stage and limited-stage small cell lung cancer. #gotoPER #ILCC2025 #lcsm
www.onclive.com/view/dr-das-...

Thanks to Dr Millie Das for meeting with us during #ILCC2025 to discuss updates to the SCLC treatment paradigm and the management of brain mets in NSCLC! See our site for #lcsm insights from Dr Das and more! #gotoPER
www.onclive.com/conference/i...

Novel Approaches Offer the Potential to Combat Immunotherapy–Refractory NSCLC Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

Novel Approaches Offer the Potential to Combat Immunotherapy–Refractory NSCLC @foxchasecancer.bsky.social #gotoPER #ILCC2025 #lcsm www.onclive.com/view/novel-a...

A huge thanks to Dr Misako Nagasaka, of @ucirvine.bsky.social, for sitting down with us at #ILCC2025 to talk about the management of NTRK+ and NRG1 fusion+ NSCLC! See our site for more meeting insights! #gotoPER #lcsm
www.onclive.com/conference/i...

Thanks to Dr Karen Reckamp, of @cedarssinaicancer.bsky.social, for stopping by during #ILCC2025 to discuss the management of RET+ NSCLC & novel therapies for patients with NSCLC without actionable mutations. Check out our site for more from the meeting! #gotoPER #lcsm
www.onclive.com/conference/i...

The final day of #ILCC2025 is here! Follow along to see which experts we speak with to close out this year's Congress, and check out our site over the next few days for even more exclusive lung cancer insights. #gotoPER #lcsm
www.onclive.com/conference/i...

New Immunotherapy Regimens Aim to Build Upon Durvalumab in Locally Advanced NSCLC Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

New Immunotherapy Regimens Aim to Build Upon Durvalumab in Locally Advanced NSCLC #ILCC2025 #lcsm #oncology www.onclive.com/view/new-imm...

Dr Jänne on Second-Line Treatment Evolutions in EGFR-Mutated NSCLC Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.

WATCH: Pasi A. Jänne, MD, PhD, discusses changes to the second-line treatment paradigm and treatment decision-making factors for patients with EGFR-mutated NSCLC.
@danafarber.bsky.social #ILCC2025 #gotoPER #lcsm
www.onclive.com/view/dr-j-nn...

Thanks to Dr Keriann Van Nostrand, of @ucsdhealth.bsky.social, for sitting down with us at #ILCC2025 to chat about the role of the pulmonologist in lung cancer screening and smoking cessation efforts! Check out our site for more #lcsm insights! #gotoPER
www.onclive.com/conference/i...

Thank you to Dr Percy Lee, of @cityofhope.bsky.social, for speaking with us at #ILCC2025 about radiation techniques for locally advanced and oligometastatic lung cancer! Head to our site for more from the meeting! #gotoPER #lcsm
www.onclive.com/conference/i...

Thanks so much to Dr Pasi Jänne, of @danafarber.bsky.social, for sitting down with us at #ILCC2025 to discuss targeted therapy for locally advanced NSCLC! Check back on our site for exclusive #lcsm perspectives from Dr Jänne and more! #gotoPER
www.onclive.com/conference/i...

Personalizing Treatment for Atypical EGFR-Mutated NSCLC Sukhmani Padda, MD, discusses ways in which evolving treatment paradigms are tailoring treatment to target atypical EGFR alterations in NSCLC.

Personalizing Treatment for Atypical EGFR-Mutated NSCLC @foxchasecancer.bsky.social #ILCC2025 #gotoPER #lcsm
www.onclive.com/view/persona...

Dr Mok on Choosing Between First-Line Therapies for BRAF-Mutant NSCLC Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

WATCH: Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer. #ILCC2025 #gotoPER #lcsm
www.onclive.com/view/dr-mok-...

Thanks to Dr Tony Mok for speaking with us at #ILCC2025 about the management of BRAF-mutant NSCLC! Head to our site to see #lcsm insights from Dr Mok and more! #gotoPER
www.onclive.com/conference/i...

Thank you to Dr Martin Dietrich for stopping by during #ILCC2025 to discuss the evolving NSCLC treatment paradigm! Check out our site for more meeting insights! #gotoPER #lcsm
www.onclive.com/conference/i...

Day 1 of the 26th Annual International Lung Cancer Congress is in full swing! Check back throughout the day for exclusive behind-the-scenes updates, and see our site for additional coverage! #gotoPER #ILCC2025 #lcsm
www.onclive.com/conference/i...